FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Professur für Hämatologie/Onkologie mit dem Schwerpunkt Tumorimmunologie
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören
Department of Medicine 5 – Haematology and Oncology
Lehrstuhl für Innere Medizin V
Overview
Publications
(103)
Research Grants
(2)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation (2024)
Richter S, Böttcher M, Stoll A, Zeremski V, Völkl S, Mackensen A, Ekici AB, et al.
Journal article
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy (2023)
Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Jacobs B, Eisenhauer N, et al.
Journal article, Letter
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib (2023)
Häselbarth L, Karow A, Mentz K, Böttcher M, Roche-Lancaster O, Krumbholz M, Jitschin R, et al.
Journal article
Role of CAR T Cell Metabolism for Therapeutic Efficacy (2022)
Rial Saborido J, Völkl S, Aigner M, Mackensen A, Mougiakakos D
Journal article, Review article
Eine übermäßige Phagozytose von Myelomzellen induziert Pyroptose in Myelom-assoziierten Makrophagen und beeinträchtigt die Wirksamkeit therapeutischer Antikörper (2022)
Flamann C, Biedermann A, Mougiakakos D, Bitterer K, Karg K, Bittenbring J, Büttner-Herold M, et al.
Conference contribution
Increased CD47 expression inhibits phagocytosis of alloreactive donor T cells after allo-HSCT (2022)
Flamann C, Matos C, Kreutz M, Shaikh H, Beilhack A, Büttner-Herold M, Lischer C, et al.
Conference contribution
Lipotoxicity as a Barrier for T Cell-Based Therapies (2022)
Boettcher-Loschinski R, Rial Saborido J, Boettcher M, Kahlfuss S, Mougiakakos D
Journal article, Review article
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience (2022)
Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, et al.
Journal article
Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021)
Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, et al.
Conference contribution
The CAR- Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL (2021)
Rejeski K, Perez-Perez A, Iacoboni G, Penack O, Buecklein VL, Jentzsch L, Mougiakakos D, et al.
Conference contribution
‹
1
2
3
...
11
›